Who and when should we screen for prostate cancer? Interviews with key opinion leaders.

Carlsson S, Leapman M, Carroll P, Schröder F, Albertsen PC, Ilic D, Barry M, Frosch DL, Vickers A., BMC Med. 13:288. doi: 10.1186/s12916-015-0526-x., 2015 Nov 27

Investigators

Dominick L. Frosch, Ph.D., Director, PAMFRI

Abstract

Prostate cancer screening using prostate-specific antigen (PSA) is highly controversial.

In this Q & A, Guest Editors for BMC Medicine's 'Spotlight on Prostate Cancer' article collection, Sigrid Carlsson and Andrew Vickers, invite some of the world's key opinion leaders to discuss who, and when, to screen for prostate cancer.
In response to the points of view from the invited experts, the Guest Editors summarize the experts' views and give their own personal opinions on PSA screening.

Pubmed Abstract

Pubmed AbstractOpens New Window